NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
Issued by National Institutes of Health · via Grants.gov — US federal funding opportunities
- Published
- 21 Nov 2024
- Closes
- 17 Nov 2026, 23:59 UTC
- Value
- USD 350,000
- Reference
- PAR-25-267
- Location
- United States
- Sector
- Healthcare & Pharma
At a glance
National Institutes of Health in United States has published a funding call in healthcare & pharma: “NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)”. Submissions close on 17 November 2026, 37 days from today. The stated value is USD 350,000. Quote reference PAR-25-267 in any correspondence with the buyer. FreeTender has recorded 430 notices from this buyer since 2023, 377 of them currently open. There are 368 open healthcare & pharma notices in United States on FreeTender. Bids are submitted to the buyer through Grants.gov — US federal funding opportunities, not through FreeTender.
Details
This notice of funding opportunity (NOFO) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this NOFO are expected to propose a multisite feasibility clinical trial that will provide new information that is scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIHs mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R01) research is scientifically necessary to design or plan the subsequent fully powered, full-scale clinical trial. Under this R01, the data collected should be used to fill gaps in scientific knowledge, including, but not limited to the following: assessing whether the intervention can be delivered with fidelity across sites; demonstrating feasibility of recruitment, accrual, and randomization of participants across sites; demonstrating participant adherence to the intervention, as well as retention of participants throughout the study across sites; refining and assessing the feasibility of protocolized multimodal interventions, and/or demonstrating feasibility of data collection across sites in preparation for a future fully powered, multisite efficacy or effectiveness trial. The need for multisite feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multisite clinical trial that has the potential to make a significant impact on public health. Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
CFDA number(s): 93.213
Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.
Context for bidders
We hold 430 notices from National Institutes of Health, going back to May 2023 — 377 of them still open. They buy mostly in Healthcare & Pharma, Education & Training and Water & Environment. There are 368 open Healthcare & Pharma tenders in United States. This one closes in 37 days.
More from this buyer
- Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed)· closes 14 Dec
- Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38 Clinical Trial Not Allowed)· closes 13 Oct
- Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)· closes 23 Nov
- Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)· closes 9 Feb
- Computational Modeling and Analysis of the Impact of Genomic Variation on Function (UM1, Clinical Trial Not Allowed)· closes 14 Dec
Similar Healthcare & Pharma tenders
- Apply for Sweetgrass Grants Program (United States)· closes 30 Nov
- Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)· closes 23 Nov
- IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)· closes 14 Dec
- Genomic Variant Interactions With Other Variants Or The Environment (UM1 Clinical Trials Not Allowed)· closes 14 Dec
- Neural Ensembles & Used Substances (NExUS) Collaboratory: Building a Multimodal Inventory of Cell Ensembles Encoding the Effects of Addictive Substances (U01 Clinical Trial Not Allowed)· closes 8 Feb
Before you bid on this tender
A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.
- Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
- Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
- Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
- Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
- Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
- Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
More Healthcare & Pharma tenders
- Повторный закуп изделий медицинского назначенияРеспубликанское государственное учреждение "Центральный военный госпиталь с поликлиникой Комитета национальной безопасности Республики Казахстан" · Kazakhstan
- О проведении государственной закупки товара для НАО «Казахский национальный медицинский университет имени С. Д. Асфендиярова» способом открытого конкурса — Аппарат искусственного кровообращенияНекоммерческое акционерное общество "Казахский национальный медицинский университет имени С. Д. Асфендиярова" · Kazakhstan
- Public notice regarding procurement of reagents for hematology analyzer at Dr Hedgewar Arogya SansthanHealth & Family Welfare Department, Govt. of NCT of Delhi · India
- услуг по медицинскому освидетельствованиюРеспубликанское государственное учреждение "Служба правительственной связи Комитета национальной безопасности Республики Казахстан" · Kazakhstan
- Государственная закупка изделий медицинского назначения для авиационного медицинского центра РГП «Казаэронавигация»Республиканское государственное предприятие на праве хозяйственного ведения "Казаэронавигация" Комитета гражданской авиации Министерства транспорта Республики Казахстан · Kazakhstan
FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.
Verify & apply on the official portal →